New Ebola strain bypasses 3.5m vaccines

Over 1,000 suspected infections. More than 240 deaths. An active war zone blocking health workers. And zero approved vaccines for the virus causing it. The outbreak in eastern Congo is exposing a blind spot that a decade of Ebola preparedness failed to close: every vaccine and treatment the world stockpiled targets a different species of the virus than the one now spreading.

A Key Cut for the Wrong Lock

The virus circulating in the DRC's Ituri Province belongs to the Bundibugyo species of Ebola, first identified in Uganda in 2007. It has appeared only twice before, in small outbreaks that barely registered internationally. That rarity is the problem. Every Ebola vaccine developed since the devastating 2014 West Africa epidemic targets the Zaire species.

Vaccines work by training the immune system to recognise a specific protein on the virus's surface, called a glycoprotein. Merck's Ervebo, the vaccine that helped end recent Zaire outbreaks, teaches the body to spot Zaire's glycoprotein. Bundibugyo's version differs by roughly 30% in its genetic sequence, enough to make the immune response unreliable, like cutting a key for the wrong lock.

The WHO convened experts in late May and concluded that evidence on cross-protection is "very limited and insufficient". A small primate study showed partial survival with the Zaire vaccine, but all vaccinated animals still developed disease. The approved antibody treatments, Inmazeb and Ebanga, are similarly not expected to work. The global stockpile holds over 3.5 million doses of Ervebo, all designed for a pathogen that isn't circulating.

Outrunning the Response

WHO declared the outbreak a Public Health Emergency of International Concern on May 17, just two days after the DRC officially announced it. That speed is unusual, and it reflects how far the virus had already traveled undetected. By the time laboratories confirmed Bundibugyo, the case count was enormous. As of early June, roughly 282 cases had been lab-confirmed with 42 deaths, while suspected cases exceeded 1,000.

Armed conflict compounds everything. The M23 rebel group controls cities in neighbouring provinces, including Goma, a city of over one million on the Rwandan border. ADF fighters killed seven people in Beni, an area also hit by the outbreak. Hundreds of diagnostic samples remain untested. Uganda has confirmed nine cases and closed its border.

Two vaccine candidates are being fast-tracked. Oxford's ChAdOx1 platform, adapted from the AstraZeneca Covid vaccine technology, could produce trial doses in two to three months. A second candidate from IAVI, which uses a harmless livestock virus as a carrier to deliver Bundibugyo proteins, needs seven to nine months. Neither has been tested in humans. Gavi has committed $50 million to accelerate production once efficacy data exists.

What Europe Learned It Can't Do

One confirmed Ebola case has reached EU soil: a US healthcare worker admitted to Berlin's Charité hospital on May 20. An Italian MSF surgeon evacuated to Rome's Spallanzani Institute tested negative. Two suspected cases in Brazil turned out to be meningitis and malaria. The ECDC assesses the risk to European citizens as very low.

The outbreak is unlikely to spread in Europe. But it has revealed an uncomfortable gap in the EU's post-Covid health architecture. HERA, the agency built to secure vaccines during emergencies, established joint procurement mechanisms and 22 strategic stockpiles across member states. That system worked for monkeypox in 2022, when an approved vaccine already existed. For Bundibugyo, there is nothing to procure. The EU has instead allocated €7.4 million to WHO for clinical trials, outsourcing a problem it cannot solve internally.

National responses remain fragmented. Italy issued a five-level risk classification with mandatory health declarations for arrivals from the DRC and Uganda. Germany relies on seven specialised isolation stations. France reinforced surveillance at Mayotte but has no unified quarantine protocol aligned with other member states.

The world spent billions preparing for the last Ebola, not the next one. Bundibugyo was a "commercially uninteresting" strain, as German health experts put it, ignored until it wasn't rare anymore. Whether this crisis catalyses investment in broad-spectrum Ebola vaccines or fades from memory once the emergency passes will tell us more about pandemic preparedness than any institutional framework on paper.